Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INO-4700

Vaccine (DNA plasmid) · Immune activation, directed at MERS-CoV spike protein · developed by INOVIO PHARMACEUTICALS

Phase 2 Most advanced trial (none active)
INO Developer
1 Registered trials

What is INO-4700?

INO-4700 is a plasmid DNA vaccine administered intradermally. It is designed to elicit immune responses against MERS-CoV and is studied in Middle East Respiratory Syndrome Coronavirus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (DNA plasmid)
Targets
MERS-CoV spike protein (antigen)
Mechanism
Immune activation, directed at MERS-CoV spike protein
Therapy area
Infectious disease
Developer
INOVIO PHARMACEUTICALS (INO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04588428 Phase 2 Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Completed INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

More from INOVIO PHARMACEUTICALS

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.

Follow INO, the company behind INO-4700

See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.